A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
← catalyst calendarNCT06618287 · readout in 1,652 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
416estimated
Sites
66
Countries
Australia, Canada, Chile +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-04 | actual | When the study began enrolling |
| Primary completion | 2031-02-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-02-26 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lung Cancer
- Breast Cancer
Interventions
- Drug: BMS-986507 — also filed as Iza-bren, Izalontamab brengitecan
- Drug: Osimertinib
- Drug: Pembrolizumab
- Drug: Nivolumab — also filed as Opdivo, BMS-936558
- Drug: Pumitamig — also filed as BMS-986545, BNT327, PM8002
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 3 years
Number of participants with serious adverse events (SAEs)
measured Up to 3 years
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera
measured Up to 3 years
Number of participants with AEs leading to discontinuation
measured Up to 3 years
Number of participants with AEs leading to death
measured Up to 3 years
Number of DLTs that occur during the DLT evaluation period
measured Up to 3 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed